Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: Significance of timing of 5-fluorouracil administration

Cancer Research

Volumn 65, Issue 2, 2005, Pages 546-552

  Seo, Emiko ^a,b   Abei, Masato ^a   Wakayama, Mariko ^a,b   Fukuda, Kuniaki ^a,b   Ugai, Hideyo ^b   Murata, Takehide ^b   Todoroki, Takeshi ^a   Matsuzaki, Yasushi ^a   Tanaka, Naomi ^a   Hamada, Hirofumi ^c   Yokoyama, Kazunari K ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b RIKEN BIORESOURCE CENTER   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; PROTEIN AXE1CAUP; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY TRACT CANCER; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG INHIBITION; ERADICATION THERAPY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS EXPRESSION; VIRUS REPLICATION;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; FEMALE; FLUOROURACIL; GALLBLADDER NEOPLASMS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PENTOSYLTRANSFERASES; TRANSDUCTION, GENETIC; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 19944431439     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-76.
2. Donohue JH, Stewart AK, Menck HR. The National Cancer Data Base Report on Carcinoma of the Gallbladder, 1989-1995. Cancer 1998;83:2618-28.
3. Schauer RJ, Meyer G, Baretton G, Schildberg FW, Rau HG. Prognostic factors and long-term results after surgery for gallbladder carcinoma: a retrospective study of 127 patients. Langenbecks Arch Surg 2001;386:110-7.
4. Henson DE, Saavedra JA, Corle D. Carcinoma of the extrahepatic bile duct. Cancer 1992;70:1498-501.
5. Nakano K, Todo T, Chijiiwa K, Tanaka M. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001;3:431-7.
6. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
7. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998;58:1946-51.
8. Koyama F, Sawada H, Fuji H, et al. Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of human colon cancer cells to 5-fluorouracil. Eur J Cancer 2000;36:2403-10.
9. Kawamura K, Tasaki K, Hamada H, Takenaga K, Sakiyama S, Tagawa M. Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity. Cancer Gene Ther 2000;7:637-43.
10. Verma IM, Somia N. Gene therapy: promises, problems and prospects. Nature 1997;389:239-42.
11. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000;105:1169-72.
12. Alemany M, Curiel DT. The development of conditionally replicative adenovirus for cancer therapy. Clin Cancer Res 2000;6:3395-9.
13. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000;19:6660-9.
14. Ries S, Korn WM. ONYX-015: mechanism of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002;86:5-11.
15. Bishoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-lacking human tumor cells. Science 1996;274:373-6.
16. Heise C, Jhoannes AS, Williams A, McCormick F, Hoff DDV, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
17. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
18. Fukuda K, Abei M, Ugai H, et al. E1A, E1B Double-Restricted oncolytic adenovirus for gene therapy of gallbladder cancer. Cancer Res 2003;63:4434-40.
19. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gallbladder. J Pathol 1993;170:67-72.
20. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-8.
21. Caca K, Feisthammel J, Klee K, et al. Inactivation of the INK4A/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 2002;97:481-8.
22. Yoshida S, Todoroki T, Ichikawa Y. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 gene in biliary tract cancers. Cancer Res 1995;55:2756-60.
23. Shi YZ, Hui AM, Li X, Takayama T, Makuuchi M. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000;6:4096-100.
24. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33.
25. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radio-sensitization. Hum Gene Ther 2000;11:67-76.
26. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999;59:410-3.
27. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999;6:57-62.
28. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000;1:56-62.
29. Wildner O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 2000;60:4167-74.
30. Lambright ES, Amin K, Wiewrodt R, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther 2001;8:946-53.
31. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;63:8743-50.
32. Ghosh M, Koike N, Yanagimoto G, et al. Establishment and characterization of unique human gallbladder cancer cell lines. Int J Oncol 2004;24:1189-96.
33. Knuth A, Gabbert H, Dippold W, et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1985;1:579-96.
34. Kanegae Y, Lee G, Sato Y, et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 1995;23:3816-21.
35. Motoi F, Sunamura M, Ding L, et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 2000;11:223-35.
36. Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full length virus genome. Proc Natl Acad Sci U S A 1996;93:1320-4.
37. Masuike T, Kikuchi K, Saito A, Hashimoto T, Takemoto Y. Determination of 5-fluorouracil incorporation into RNA in tissue using gas chromatography-mass spectrometry. Antibiot Chemother 1995;11:162-7.
38. Nakamura H, Mullen JT, Chandrasekhar S, Pwlik TK, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that express yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001;61:5447-52.
39. Ahgi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999;59:3861-5.
40. Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the oncolytic effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther 2000;7:939-46.
41. Carroll NM, Chase M, Chiocca EA. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res 1997;69:413-7.
42. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76.
43. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
44. Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV1 mass distribution in a rodent brain tumor model. Gene Ther 2000;7:1648-55.
45. Jacobs A, Tjuvajev JG, Dubrovin M, et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001;61:2983-95.
46. Peng KW, Facteau S, Wegman T, O'Kane D, Russel SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8:527-31.
47. Bernt KM, Steinwaerder DS, Ni S, Li Z-Y, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002;62:6089-98.
48. Oonuma M, Sunamura M, Motoi F, et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer 2002;102:51-9.